Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
HYPAQUE-CYSTO is a urethral solution diagnostic agent approved in 1969 by GE HealthCare for cystographic imaging procedures. The product is a contrast medium used to visualize the urinary bladder and urethra during diagnostic imaging. It represents a legacy radiographic diagnostic tool in the urology and radiology space.
This legacy diagnostic product faces declining utilization as advanced imaging modalities (ultrasound, MRI, CT) replace traditional cystography, with minimal team expansion expected.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on HYPAQUE-CYSTO offers limited career trajectory given its LOE-approaching status and zero linked job postings; roles focus on end-of-life management, pricing optimization, and portfolio transition planning. This assignment is typically suited for professionals with legacy product expertise or those seeking to develop operational efficiency and wind-down management competencies.
Worked on HYPAQUE-CYSTO at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.